GlassScriptPhysician profile
Leon W Kao
NPI 1265639728
$7,693.15
in general payments reported to CMS, 2019-2025
33 companies · $1,657 in 2025
The $1,657 reported for 2025 was more than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $589 · 2020: $637 · 2021: $828 · 2022: $1,124 · 2023: $1,169 · 2024: $1,689 · 2025: $1,657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,469 · Education: $23.31 · Consulting Fee: $23.26.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,468.83 |
| Education | $23.31 |
| Consulting Fee | $23.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,374.87 | 2019-2025 | Tezspire, Fasenra, Airsupra |
| Glaxosmithkline, LLC. | $1,199.02 | 2019-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Regeneron Healthcare Solutions, INC. | $1,026.90 | 2019-2025 | Dupixent |
| Genzyme Corporation | $890.21 | 2019-2025 | |
| Kaleo, INC. | $427.26 | 2019-2023 | Auvi-Q |
| Pfizer INC. | $309.83 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $279.61 | 2020-2025 | Cuvitru, Takhzyro |
| Genentech USA, INC. | $243.47 | 2019-2025 | Xolair |
| Optinose US, INC. | $238.92 | 2019-2025 | |
| Grifols USA, LLC | $230.65 | 2022-2025 | Xembify, Prolastin-C Liquid |
| Incyte Corporation | $227.18 | 2021-2025 | Opzelura |
| Novartis Pharmaceuticals Corporation | $219.83 | 2019-2025 | |
| Amgen INC. | $157.99 | 2022-2025 | Tezspire |
| Ars Pharmaceuticals Operations, INC. | $155.86 | 2025 | Neffy |
| Biocryst US Sales Co., LLC | $92.93 | 2022-2025 | Orladeyo |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.90 | 2019-2022 | |
| Phadia US INC. | $59.05 | 2021-2024 | Immunocap |
| Aimmune Therapeutics, INC. | $57.92 | 2021-2022 | |
| Galderma Laboratories, L.P. | $54.15 | 2025 | Nemluvio |
| Teva Pharmaceuticals USA, INC. | $45.85 | 2020 | |
| Greer Laboratories, INC. | $41.39 | 2025 | Oralair |
| Octapharma USA, INC. | $40.21 | 2023 | Cutaquig |
| Invivyd INC | $31.10 | 2024 | Pemgarda |
| Organon LLC | $29.84 | 2025 | Vtama |
| Ionis Pharmaceuticals, INC. | $26.19 | 2025 | Dawnzera |
| Eyevance Pharmaceuticals LLC | $26.00 | 2020-2021 | |
| Lilly USA, LLC | $25.35 | 2025 | Taltz, Ebglyss |
| Adma Biomanufacturing LLC | $23.26 | 2025 | |
| Dermavant Sciences, INC. | $19.63 | 2024 | Vtama |
| Blueprint Medicines Corporation | $18.34 | 2022 | |
| Abbvie INC. | $14.83 | 2023 | |
| Leo Pharma INC. | $13.57 | 2022 | |
| Merck Sharp & Dohme LLC | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leon Kao listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.